Introduction/Background Preoperative uterovaginal brachytherapy at dose of 60 Gy is a therapeutic option for patients with localized cervical cancer. In our study, we will evaluate the dose received by the ovaries of these patients.

Methodology This is a prospective study of eighteen premenopausal patients with cervical cancer treated at the Salah Azaiez Institute between December 2018 and March 2019. These patients received uterovaginal brachytherapy. the minimal and mean doses received by left and right ovaries were evaluated. We also evaluated the doses received by a volume formed by the ovaries to which predictive margins for their mobility were added.

This volume is defined by a margin of 3.8 cm in longitudinal and 3.3cm in anteroposterior and 5.8 cm in lateral for the right ovary.

It is defined by a margin of 5.3 cm in longitudinal and 7.8 cm in anteroposterior and 1.7 cm in lateral for the left ovary.

Results The age of the patients was between 25 and 45 years old. For the right ovary, the average of minimal dose was 9.67Gy (3.12–33.6). The average of mean dose was 15.87 Gy (6.12–54). For the predictive volume of right ovarian mobility,the average of minimal dose was 3.83 GY (1.36–15.28) and the average of mean dose received by this volume was 19.99GY (6.64–66.8). For the left ovary, the average of minimal dose was 9.62Gy (5.2–26). The average of mean dose was 15.75Gy (4.8–55.6). For the predictive volume of left ovarian mobility, the average of minimal dose was 4.14 GY (2.8–13.48) and the average of mean dose was 17.07 GY (5.34–77.6).

Conclusion Uterovaginal Brachytherapy may cause early menopause by delivering more than the tolerance dose to the ovaries. Ovarian transposition should be offered to premenopausal patients.

Disclosure Nothing to disclose.